Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$20.50 -1.1%	$20.98	$17.24 ▼ $28.56	$13.15B	0.96	1.22 million shs	727,649 shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$66.26 ▼ $131.98	$14.05B	0.69	1.52 million shs	N/A
TPTX Turning Point Therapeutics	$76.01	$75.83	$23.77 ▼ $82.20	$3.81B	-0.18	1.14 million shs	4,322 shs
UTHR United Therapeutics	$284.27 +0.1%	$301.12	$266.98 ▼ $417.82	$12.82B	0.57	446,107 shs	462,927 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	0.00%	-3.12%	-3.85%	+3.02%	-20.14%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+0.05%	+85.50%
TPTX Turning Point Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
UTHR United Therapeutics	0.00%	-2.23%	-11.27%	-7.39%	-10.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	4.1008 of 5 stars	3.3	5.0	0.0	0.0	3.4	0.0	3.1
ITCI Intra-Cellular Therapies	0.8937 of 5 stars	1.1	0.0	0.0	4.5	0.0	1.7	0.6
TPTX Turning Point Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	4.9926 of 5 stars	4.3	5.0	0.0	4.6	2.7	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.67	Moderate Buy	$37.60	83.41% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
TPTX Turning Point Therapeutics	0.00	N/A	N/A	N/A
UTHR United Therapeutics	2.69	Moderate Buy	$393.08	38.28% Upside

Current Analyst Ratings Breakdown

Latest TPTX, ITCI, GMAB, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$321.00 ➝ $315.00
6/2/2025	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$405.00
5/5/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00
5/1/2025	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$346.00 ➝ $348.00
5/1/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$355.00 ➝ $350.00
4/25/2025	UTHR United Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$395.00 ➝ $314.00
4/21/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$357.00 ➝ $355.00
4/21/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$314.00 ➝ $314.00
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.21	$1.52 per share	13.52	$8.04 per share	2.55
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
TPTX Turning Point Therapeutics	$30.83M	123.46	N/A	N/A	$15.84 per share	4.80
UTHR United Therapeutics	$2.88B	4.46	$28.40 per share	10.01	$144.34 per share	1.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	11.65	11.52	6.76	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
TPTX Turning Point Therapeutics	-$236.55M	-$6.90	N/A	N/A	N/A	N/A	-37.45%	-35.62%	N/A
UTHR United Therapeutics	$1.20B	$25.06	11.34	10.34	6.22	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest TPTX, ITCI, GMAB, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
TPTX Turning Point Therapeutics	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.34	5.32
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
TPTX Turning Point Therapeutics	N/A	16.83	16.83
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
TPTX Turning Point Therapeutics	90.33%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
TPTX Turning Point Therapeutics	8.60%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.22 million	631.35 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
TPTX Turning Point Therapeutics	250	50.07 million	45.77 million	Not Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

TPTX, ITCI, GMAB, and UTHR Headlines

Recent News About These Companies

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

June 29 at 4:19 AM | americanbankingnews.com

United Therapeutics Corporation (UTHR) - Yahoo Finance

June 28 at 2:23 PM | finance.yahoo.com

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares

June 28 at 6:13 AM | insidertrades.com

United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study

June 28 at 5:24 AM | msn.com

UTHR United Therapeutics Corporation - Seeking Alpha

June 27 at 7:22 PM | seekingalpha.com

Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

June 27 at 5:55 PM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.

June 27 at 8:19 AM | marketbeat.com

Robeco Institutional Asset Management B.V. Buys 34,362 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

June 27 at 5:02 AM | marketbeat.com

Contrasting United Therapeutics (NASDAQ:UTHR) and Journey Medical (NASDAQ:DERM)

June 27 at 2:26 AM | americanbankingnews.com

United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment

June 26 at 12:40 PM | tipranks.com

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

June 26 at 10:45 AM | zacks.com

3D Systems and TISSIUM Achieve FDA Approval for Innovative 3D-Printed Solution in Peripheral Nerve Repair

June 26 at 9:24 AM | quiverquant.comQ

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in Stock

June 26 at 7:12 AM | insidertrades.com

Brokerages Set United Therapeutics Corporation (NASDAQ:UTHR) Price Target at $393.08

June 26 at 2:41 AM | americanbankingnews.com

Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Corp

June 25, 2025 | gurufocus.com

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells $187,043.55 in Stock

June 25, 2025 | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Director Sells 3,036 Shares of Stock

June 25, 2025 | marketbeat.com

5 Must-Read Analyst Questions From United Therapeutics’s Q1 Earnings Call

June 25, 2025 | msn.com

Oppenheimer Asset Management Inc. Has $5.28 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

June 25, 2025 | marketbeat.com

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

June 24, 2025 | bakersfield.comB

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

June 24, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPTX, ITCI, GMAB, and UTHR Company Descriptions

Genmab A/S NASDAQ:GMAB

$20.50 -0.23 (-1.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$21.34 +0.84 (+4.12%)

As of 06/27/2025 05:12 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$284.27 +0.18 (+0.06%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$282.42 -1.84 (-0.65%)

As of 06/27/2025 05:34 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time